Literature DB >> 2474375

Antigenic sites in carcinoembryonic antigen.

S Hammarstrom1, J E Shively, R J Paxton, B G Beatty, A Larsson, R Ghosh, O Bormer, F Buchegger, J P Mach, P Burtin.   

Abstract

The epitope reactivities of 52 well-characterized monoclonal antibodies (Mabs) against carcinoembryonic antigen from 11 different research groups were studied using competitive solid-phase immunoassays. About 60% of all possible combinations of Mabs as inhibitors and as the primary binding antibody were investigated. The inhibition data were analyzed by a specially developed computer program "EPITOPES" which measures concordance and discordance in inhibition patterns between Mabs. The analysis showed that 43 of the 52 Mabs (83%) could be classified into one of five essentially noninteracting epitope groups (GOLD 1-5) containing between four and 15 Mabs each. The epitopes recognized by the Mabs belonging to groups 1 to 5 were peptide in nature. With one or two possible exceptions non-classifiable Mabs were either directed against carbohydrate epitopes (4 Mabs) or were inactive in the tests used. Within epitope groups GOLD 1, 4, and 5 two partially overlapping subgroups were distinguished. Mabs with a high degree of carcinoembryonic antigen specificity generally belonged to epitope groups GOLD 1 and 3.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474375

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  In-cell PCR from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cells.

Authors:  M J Embleton; G Gorochov; P T Jones; G Winter
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

2.  scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.

Authors:  Bianca Ferrarini Zanetti; Camila Pontes Ferreira; José Ronnie Carvalho de Vasconcelos; Sang Won Han
Journal:  Gene Ther       Date:  2019-02-15       Impact factor: 5.250

3.  The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.

Authors:  Nathalie Kersual; Véronique Garambois; Thierry Chardès; Jean-Pierre Pouget; Imed Salhi; Caroline Bascoul-Mollevi; Frédéric Bibeau; Muriel Busson; Henri Vié; Béatrice Clémenceau; Christian K Behrens; Pauline Estupina; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker.

Authors:  A Schott; I Vogel; U Krueger; H Kalthoff; H W Schreiber; W Schmiegel; D Henne-Bruns; B Kremer; H Juhl
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

5.  Classification and localisation of carcinoembryonic antigen (CEA) related antigen expression in normal oesophageal squamous mucosa and squamous carcinoma.

Authors:  D S Sanders; C A Wilson; F J Bryant; J Hopkins; G D Johnson; D M Milne; M A Kerr
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

6.  Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.

Authors:  Marc Ychou; David Azria; Cathy Menkarios; Patrick Faurous; François Quenet; Bernard Saint-Aubert; Philippe Rouanet; Monique Pèlegrin; Caroline Bascoul-Mollevi; Dominique Guerreau; Jean-Claude Saccavini; Jean-Pierre Mach; Jean-Claude Artus; André Pèlegrin
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

7.  Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas.

Authors:  Seong-Hoon Park; Ki-Beom Ku; Ho-Young Chung; Wansik Yu
Journal:  Cancer Res Treat       Date:  2008-03-31       Impact factor: 4.679

8.  Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.

Authors:  Lore Santoro; Samir Boutaleb; Véronique Garambois; Caroline Bascoul-Mollevi; Vincent Boudousq; Pierre-Olivier Kotzki; Monique Pèlegrin; Isabelle Navarro-Teulon; André Pèlegrin; Jean-Pierre Pouget
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

9.  The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.

Authors:  Li Peng; Michael D Oberst; Jiaqi Huang; Philip Brohawn; Chris Morehouse; Kristen Lekstrom; Patrick A Baeuerle; Herren Wu; Yihong Yao; Steven R Coats; William Dall'Acqua; Melissa Damschroder; Scott A Hammond
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

10.  Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.

Authors:  C A Vogel; A Bischof-Delaloye; J P Mach; A Pèlegrin; N Hardman; B Delaloye; F Buchegger
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.